Wet (Neovascular / Exudative) Macular Degeneration Global Therapeutic Clinical Trials Review, H2, 2018

GlobalData
359 Pages - GLDATA66246
$2,500.00

Summary

GlobalData's clinical trial report, “Wet (Neovascular / Exudative) Macular Degeneration Global Clinical Trials Review, H2, 2018" provides an overview of Wet (Neovascular / Exudative) Macular Degeneration clinical trials scenario. This report provides top line data relating to the clinical trials on Wet (Neovascular / Exudative) Macular Degeneration. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.



Companies Mentioned
Novartis AG
Bayer AG
Regeneron Pharmaceuticals Inc
F. Hoffmann-La Roche Ltd
Pfizer Inc
Ophthotech Corp
Allergan Plc
Chengdu Kanghong Pharmaceuticals Group Co Ltd
Ohr Pharmaceutical Inc
Bausch Health Companies Inc

'

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
GlobalData Clinical Trials Report Coverage 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Five Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Wet (Neovascular / Exudative) Macular Degeneration to Ophthalmology Clinical Trials 16
Clinical Trials by Phase in G7 Countries 18
Clinical Trials in G7 Countries by Trial Status 19
Clinical Trials by E7 Countries: Proportion of Wet (Neovascular / Exudative) Macular Degeneration to Ophthalmology Clinical Trials 21
Clinical Trials by Phase in E7 Countries 23
Clinical Trials in E7 Countries by Trial Status 24
Clinical Trials by Phase 26
In Progress Trials by Phase 27
Clinical Trials by Trial Status 28
Clinical Trials by End Point Status 30
Subjects Recruited Over a Period of Time 31
Clinical Trials by Sponsor Type 32
Prominent Sponsors 33
Top Companies Participating in Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials 35
Prominent Drugs 37
Latest Clinical Trials News on Wet (Neovascular / Exudative) Macular Degeneration 39
Jul 02, 2018: Elsalys Biotech : New studies confirm anti-CD160 potential in ophthalmology 39
Jul 02, 2018: Opthea’s Phase 2b Wet AMD Clinical Trial Reaches Mid-Way Point of Patient Recruitment 40
Clinical Trial Profile Snapshots 41
Appendix 357
Abbreviations 357
Definitions 357
Research Methodology 358
Secondary Research 358
About GlobalData 358
Contact Us 359
Source 359

List of Tables
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials by Region, 2018* 7
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 11
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 12
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, North America, Top Countries, 2018* 13
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018* 14
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2018* 15
Proportion of Wet (Neovascular / Exudative) Macular Degeneration to Ophthalmology Clinical Trials, G7 Countries (%), 2018* 17
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 18
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 20
Proportion of Wet (Neovascular / Exudative) Macular Degeneration to Ophthalmology Clinical Trials, E7 Countries (%), 2018* 22
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 23
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 25
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials by Phase, 2018* 26
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 27
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials by Trial Status, 2018* 29
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Global, by End Point Status, 2018* 30
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 31
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 32
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 34
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 36
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 38

List of Figures
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials by Region (%), 2018* 7
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 8
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 11
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 12
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 13
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018* 14
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2018* 15
Proportion of Wet (Neovascular / Exudative) Macular Degeneration to Ophthalmology Clinical Trials, G7 Countries (%), 2018* 16
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 18
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 19
Proportion of Wet (Neovascular / Exudative) Macular Degeneration to Ophthalmology Clinical Trials, E7 Countries (%), 2018* 21
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 23
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 24
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials by Phase (%), 2018* 26
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 27
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials by Trial Status, 2018* 28
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Global, by End Point Status, 2018* 30
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 31
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 32
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 33
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 35
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 37
GlobalData Methodology 358

$2,500.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838



Browse All Reports